Minimally Invasive Septal Myectomy for the Treatment of @entity1121 and Intrinsic XXXX .

@entity1 @entity712 @entity339 @entity3585 @entity1757 @entity179 @entity1121
OBJECTIVE: Transaortic left ventricular septal myectomy described by Morrow is a classical procedure for the treatment of systolic anterior motion of the mitral apparatus associated with @entity1121 ( @entity1121 ). We aimed to review our results of transmitral septal myectomy and mitral valve repair/replacement in @entity1 with @entity339 associated with @entity1121 , operated on through a minimally invasive approach. METHODS: Between 2005 and 2014, 19 @entity1 [7 @entity1 (37%); mean (SD) age, 69.4 (14.5) years] were treated with minimally invasive approach for @entity339 and @entity1121 . Preoperative peak left ventricular outflow tract (LVOT) gradient was 66 (24) mm Hg. Severe @entity339 was diagnosed in 16 cases (84%). New York Heart Association functional class III to IV @entity712 was present in 13 @entity1 (68%). RESULTS: Fifteen @entity1 (79%) underwent mitral valve replacement, and four @entity1 (21%) underwent mitral valve repair. @entity3585 was corrected directly in all @entity1 via the mitral valve with septal myectomy/myotomy, avoiding aortotomy in majority of the @entity1 . No significant prolongation of extracorporeal circulation/aortic cross-clamping times was observed (P = 0.41 and P = 0.67, respectively) when compared with a similar population without @entity1121 . No iatrogenic @entity1757 developed in treated @entity1 . No hospital mortality occurred. Resting LVOT gradient reduced at discharge to 13 (22) mm Hg (P = 0.025). CONCLUSIONS: Transmitral left ventricular septal myectomy in @entity1 with @entity179 is quite a simple, feasible, and effective technique and does not require aortotomy in most cases. It can be performed with low early mortality and satisfactory resolution of @entity3585 in a minimally invasive setting.
